ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of “Moderate Buy” from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $107.3333.

Several research firms have recently weighed in on ANIP. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $84.11 on Tuesday. The company has a market capitalization of $1.91 billion, a PE ratio of 21.29 and a beta of 0.44. The company has a 50 day simple moving average of $80.70 and a two-hundred day simple moving average of $79.34. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals has a fifty-two week low of $62.60 and a fifty-two week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. The business had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts anticipate that ANI Pharmaceuticals will post 8.03 earnings per share for the current year.

Insider Activity at ANI Pharmaceuticals

In other news, Director Patrick D. Walsh sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total transaction of $806,300.00. Following the completion of the sale, the director owned 38,432 shares of the company’s stock, valued at $3,098,772.16. This trade represents a 20.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $82.03, for a total transaction of $41,015.00. Following the sale, the vice president directly owned 77,890 shares of the company’s stock, valued at approximately $6,389,316.70. This trade represents a 0.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 79,016 shares of company stock worth $6,195,991. Corporate insiders own 8.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Several large investors have recently modified their holdings of ANIP. KBC Group NV acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at about $28,000. Hantz Financial Services Inc. grew its stake in shares of ANI Pharmaceuticals by 70.3% in the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 249 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at about $48,000. Finally, State of Wyoming acquired a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.